In Latest NewsPosted April 15, 2021 Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer
In Latest NewsPosted March 4, 2021 ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
In Latest NewsPosted December 1, 2020 Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer